Core Viewpoint - He Yu-B (02256) has seen its stock price rise over 4%, reaching a historical high of 13.67 HKD, with a year-to-date increase of nearly 100% [1] Financial Performance - For the first half of the year, the company reported revenue of 612 million RMB, representing a year-on-year growth of 21.5% [1] - The net profit attributable to shareholders was 328 million RMB, showing a significant year-on-year increase of 58.8% [1] Research and Development - The company has increased its R&D expenses by 6% year-on-year, indicating a commitment to innovation [1] - Management expenses have decreased by 13%, contributing to improved profitability [1] Financial Guidance - The company has guided that its operating cash consumption for the year will remain within 570 million RMB, with expectations of maintaining profitability [1] Market Valuation and Future Prospects - Citigroup believes the current valuation of He Yu-B is low, considering the high certainty of its two late-stage drug candidates, pimicotinib and irpagratinib [1] - The success rate of the phase III clinical trial for irpagratinib in second-line liver cancer is expected to be very high, which should be factored into its valuation [1] - Key catalysts are anticipated in 2025 and 2026, including the approval and commercialization of pimicotinib, phase III data for irpagratinib, and updates on other candidates like ABSK043 and ABSK061 [1]
港股异动 | 和誉-B(02256)再涨超4% 股价续刷历史新高 年内股价累涨近两倍